{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T09:45:47Z","timestamp":1772271947394,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T00:00:00Z","timestamp":1623801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008732","name":"Uehara Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003083","name":"European Association of Urology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003083","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.ctrv.2021.102242","type":"journal-article","created":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T11:18:00Z","timestamp":1623496680000},"page":"102242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6147-6569","authenticated-orcid":false,"given":"Keiichiro","family":"Mori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8163-6953","authenticated-orcid":false,"given":"Fahad","family":"Quhal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadi","family":"Mostafaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8953-0272","authenticated-orcid":false,"given":"Ekaterina","family":"Laukhtina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor M.","family":"Schuettfort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1625-1077","authenticated-orcid":false,"given":"David","family":"D'Andrea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Egawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Bensalah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Schmidinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Powles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2021.102242_b0005","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.eururo.2020.12.005","article-title":"Updated european association of urology guidelines on renal cell carcinoma: nivolumab plus cabozantinib joins immune checkpoint inhibition combination therapies for treatment-na\u00efve metastatic clear-cell renal cell carcinoma","volume":"79","author":"Bedke","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2021.102242_b0010","article-title":"The predictive value of programmed death ligand 1 in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors: a systematic review and meta-analysis","author":"Mori","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2021.102242_b0015","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1177\/1078155221989424","article-title":"Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 in renal cell carcinoma: lessons from CheckMate 9ER and IMmotion 151","volume":"27","author":"Khalil","year":"2021","journal-title":"J Oncol Pharm Pract: Off Publ Int Soc Oncol Pharm Practitioners"},{"key":"10.1016\/j.ctrv.2021.102242_b0020","article-title":"Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis","volume":"363","author":"Xu","year":"2018","journal-title":"BMJ (Clinical research ed)."},{"key":"10.1016\/j.ctrv.2021.102242_b0025","doi-asserted-by":"crossref","first-page":"v527","DOI":"10.1093\/annonc\/mdz253.122","article-title":"Immune-related adverse events (irAEs) with single-agent PD-1 vs PD-L1 inhibitors: A meta-analysis of 8,730 patients from clinical trials","volume":"30","author":"Sonpavde","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2021.102242_b0030","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.2217\/fon-2018-0868","article-title":"Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis","volume":"15","author":"Tartarone","year":"2019","journal-title":"Fut Oncol (London, England)."},{"key":"10.1016\/j.ctrv.2021.102242_b0035","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00262-020-02684-8","article-title":"Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis","volume":"70","author":"Mori","year":"2021","journal-title":"Can Immunol Immunotherapy: CII"},{"key":"10.1016\/j.ctrv.2021.102242_b0040","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamaoncol.2019.5367","article-title":"Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis","volume":"6","author":"Duan","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2021.102242_b0045","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet (London, England)."},{"key":"10.1016\/j.ctrv.2021.102242_b0050","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"New England J Med"},{"key":"10.1016\/j.ctrv.2021.102242_b0055","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.annonc.2020.04.010","article-title":"Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma","volume":"31","author":"Choueiri","year":"2020","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2021.102242_b0060","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ctrv.2021.102242_b0065","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ctrv.2021.102242_b0070","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2021.102242_b0075","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","author":"Motzer","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ctrv.2021.102242_b0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.ctrv.2021.102242_b0085","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ (Clinical research ed)."},{"key":"10.1016\/j.ctrv.2021.102242_b0090","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1472-6963-4-38","article-title":"Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group","volume":"4","author":"Atkins","year":"2004","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.ctrv.2021.102242_b0095","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ctrv.2021.102242_b0100","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1470-2045(14)71222-7","article-title":"The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study","volume":"16","author":"Ko","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2021.102242_b0105","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cct.2006.04.004","article-title":"Random-effects model for meta-analysis of clinical trials: an update","volume":"28","author":"DerSimonian","year":"2007","journal-title":"Contemporary Clinical Trials"},{"key":"10.1016\/j.ctrv.2021.102242_b0110","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ctrv.2021.102242_b0115","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clin Res ed)."},{"key":"10.1016\/j.ctrv.2021.102242_b0120","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/jrsm.1054","article-title":"Automating network meta-analysis","volume":"3","author":"van Valkenhoef","year":"2012","journal-title":"Res Synthesis Methods"},{"key":"10.1016\/j.ctrv.2021.102242_b0125","unstructured":"Dias S, Welton NJ, Sutton AJ, Ades AE. NICE Decision Support Unit Technical Support Documents. NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials. London: National Institute for Health and Care Excellence (NICE) Copyright \u00a9 2014 National Institute for Health and Clinical Excellence, unless otherwise stated. All rights reserved.; 2014."},{"key":"10.1016\/j.ctrv.2021.102242_b0130","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1471-2288-10-54","article-title":"Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial","volume":"10","author":"Woods","year":"2010","journal-title":"BMC Med Res Method"},{"key":"10.1016\/j.ctrv.2021.102242_b0135","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Method"},{"key":"10.1016\/j.ctrv.2021.102242_b0140","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ctrv.2021.102242_b0145","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1158\/1078-0432.CCR-19-3323","article-title":"Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting","volume":"26","author":"Aggen","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2021.102242_b0150","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1158\/1078-0432.CCR-16-1761","article-title":"PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer","volume":"23","author":"Yearley","year":"2017","journal-title":"Clin Can Res: Off J Am Assoc Can Res"},{"key":"10.1016\/j.ctrv.2021.102242_b0155","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00262-018-2263-4","article-title":"Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment","volume":"68","author":"Umezu","year":"2019","journal-title":"Can Immunol Immunother : CII."},{"key":"10.1016\/j.ctrv.2021.102242_b0160","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1460298","article-title":"PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab","volume":"7","author":"George","year":"2018","journal-title":"Oncoimmunology."},{"key":"10.1016\/j.ctrv.2021.102242_b0165","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1172\/JCI80011","article-title":"Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future","volume":"125","author":"Chen","year":"2015","journal-title":"J Clin Investig"},{"key":"10.1016\/j.ctrv.2021.102242_b0170","doi-asserted-by":"crossref","unstructured":"Poggio M, Hu T, Pai CC, Chu B, Belair CD, Chang A, et al. Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory. Cell. 2019;177:414-27.e13.","DOI":"10.1016\/j.cell.2019.02.016"},{"key":"10.1016\/j.ctrv.2021.102242_b0175","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1084\/jem.20180870","article-title":"Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer","volume":"216","author":"Gong","year":"2019","journal-title":"J Exp Med"},{"key":"10.1016\/j.ctrv.2021.102242_b0180","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41577-019-0264-y","article-title":"The importance of exosomal PDL1 in tumour immune evasion","volume":"20","author":"Daassi","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ctrv.2021.102242_b0185","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/s41422-018-0060-4","article-title":"Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth","volume":"28","author":"Yang","year":"2018","journal-title":"Cell Res"},{"key":"10.1016\/j.ctrv.2021.102242_b0190","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","article-title":"Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response","volume":"560","author":"Chen","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2021.102242_b0195","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1158\/2326-6066.CIR-15-0059","article-title":"Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells","volume":"3","author":"Boyerinas","year":"2015","journal-title":"Can Immunol Res."},{"key":"10.1016\/j.ctrv.2021.102242_b0200","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1200\/JCO.2019.37.15_suppl.101","article-title":"Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)","volume":"37","author":"Choueiri","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102242_b0205","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2021.102242_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2021.04.042","article-title":"The 2021 updated European association of urology guidelines on renal cell carcinoma: immune checkpoint inhibitor-based combination therapies for treatment-naive metastatic clear-cell renal cell carcinoma are standard of care","author":"Bedke","year":"2021","journal-title":"Eur Urol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737221000906?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737221000906?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:26:46Z","timestamp":1759656406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737221000906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":42,"alternative-id":["S0305737221000906"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2021.102242","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2021.102242","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102242"}}